A comparison of lanreotide and octreotide LAR for treatment of acromegaly.

Turner HE, Vadivale A, Keenan J, Wass JA

Clinical endocrinology1 Sept 1999Cited by 49 (Europe PMC)

PMID10469005DOI10.1046/j.1365-2265.1999.00853.xPepBankPUB-10469005

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In acromegaly, six patients (60%) achieved target mean GH on octreotide LAR 20 mg.
In plain wordsIn acromegaly, six patients (60%) achieved the GH target with octreotide LAR 20 mg.
Peptide
Octreotide
Outcome
Not applicableTarget mean GH at 20 mg
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mgAs given in this study (human).
Measurements
Patients achieving mean GH < 5 mU/l
6 patients
octreotide LAR 20 mg
Patients achieving mean GH < 5 mU/l
60%
octreotide LAR 20 mg
Source sentences
Summary
On 20 mg octreotide LAR, 6 (60%) patients achieved the target mean GH and a further 2 (80%) when the dose was increased to 30 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
We prospectively studied 10 unselected patients with acromegaly who were treated first with lanreotide (LAN) and then octreotide LAR (LAR) following a washout period.
Report a problemFND-1046900501
02HumanNon-randomized trialEfficacy outcome
In acromegaly, two further patients achieved target mean GH after octreotide LAR increased to 30 mg, bringing the proportion to 80%.
In plain wordsIn acromegaly, 80% achieved the GH target after octreotide LAR increased to 30 mg.
Peptide
Octreotide
Outcome
Not applicableTarget mean GH after dose increase
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mgAs given in this study (human).
Measurements
Additional patients achieving mean GH < 5 mU/l
2 patients
octreotide LAR increased to 30 mg
Patients achieving mean GH < 5 mU/l
80%
octreotide LAR increased to 30 mg
Source sentences
Summary
On 20 mg octreotide LAR, 6 (60%) patients achieved the target mean GH and a further 2 (80%) when the dose was increased to 30 mg.
1 context sentence(design, population, supporting numbers)
Summary · context
We prospectively studied 10 unselected patients with acromegaly who were treated first with lanreotide (LAN) and then octreotide LAR (LAR) following a washout period.
Report a problemFND-1046900502
03HumanNon-randomized trialEfficacy outcome
In acromegaly, IGF-1 normalized in 7/10 patients (70%) receiving octreotide LAR.
In plain wordsIn acromegaly, IGF-1 normalized in 7/10 patients receiving octreotide LAR.
Peptide
Octreotide
Outcome
Not applicableIGF-1 normalization
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Measurements
Patients with normalized IGF-1
7 patients
octreotide LAR; of 10 patients
Patients with normalized IGF-1
70%
octreotide LAR
Source sentences
Summary
Normalization of IGF-1 occurred in 5/9 (55.6%) patients who received lanreotide and 7/10 (70%) of those who received octreotide LAR.
1 context sentence(design, population, supporting numbers)
Summary · context
We prospectively studied 10 unselected patients with acromegaly who were treated first with lanreotide (LAN) and then octreotide LAR (LAR) following a washout period.
Report a problemFND-1046900503
04HumanNon-randomized trialEfficacy outcome
In acromegaly, octreotide LAR 20 mg every 4 weeks produced lower mean GH than lanreotide 30 mg every 10 days (P = 0.037).
In plain wordsIn acromegaly, octreotide LAR produced lower mean GH than lanreotide at the compared standard doses.
Peptide
Octreotide
Outcome
DecreaseMean GH with standard dosing
Study
n: not reported in source
Comparator
Lanreotide 30 mg every 10 days
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 mg every 4 weeksAs given in this study (human).
Source sentences
Summary
The patients' mean GH was significantly lower when treated with octreotide LAR 20 mg every 4 weeks compared with lanreotide 30 mg every 10 days (P = 0.037).
1 context sentence(design, population, supporting numbers)
Summary · context
We prospectively studied 10 unselected patients with acromegaly who were treated first with lanreotide (LAN) and then octreotide LAR (LAR) following a washout period.
Report a problemFND-1046900504
05HumanNon-randomized trialEfficacy outcome
In acromegaly, maximal mean GH suppression was greater with octreotide LAR 30 mg than lanreotide every 7 days (P < 0.02).
In plain wordsIn acromegaly, octreotide LAR 30 mg suppressed mean GH more than lanreotide every 7 days.
Peptide
Octreotide
Outcome
DecreaseMaximal mean GH suppression
Study
n: not reported in source
Comparator
Lanreotide every 7 days
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
30 mgAs given in this study (human).
Source sentences
Summary
Maximal suppression of mean GH with 30 mg octreotide LAR or 7 day dosing of lanreotide was significantly greater on octreotide LAR (P < 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
We prospectively studied 10 unselected patients with acromegaly who were treated first with lanreotide (LAN) and then octreotide LAR (LAR) following a washout period.
Report a problemFND-1046900505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT00461149

Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

Federico II Universityn = 50Jan 1995 to Dec 2006

Acromegaly

Trial page ClinicalTrials.govUpdated 17 Apr 2007

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC